Evidence map›Paper›PMID 38116008›Full record

ReviewFrontiers in immunology2023

Overview of anti-viral effects of probiotics via immune cells in pre-, mid- and post-SARS-CoV2 era.

Osamu Kanauchi, Zhao Xuan Low, Kenta Jounai, Ryohei Tsuji, Sazaly AbuBakar

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Frontiers in immunology · 2025
    Pooled it
  2. Review
  3. Effects ofTropical medicine and infectious disease · 2026
    Article
  4. The Therapeutic Administration ofMicroorganisms · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Osamu KanauchiTropical Infectious Disease Research and Education Centre (TIDREC), Institute for Advanced Studies, University of Malaya, Kuala Lumpur, Malaysia.
Zhao Xuan LowTropical Infectious Disease Research and Education Centre (TIDREC), Institute for Advanced Studies, University of Malaya, Kuala Lumpur, Malaysia.
Kenta JounaiInstitute of Health Sciences, Kirin Holdings Co., Ltd., Fujisawa, Japan.
Ryohei TsujiInstitute of Health Sciences, Kirin Holdings Co., Ltd., Fujisawa, Japan.
Sazaly AbuBakarTropical Infectious Disease Research and Education Centre (TIDREC), Institute for Advanced Studies, University of Malaya, Kuala Lumpur, Malaysia.
Kirin (Japan) · JPUniversity of Malaya · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 outbreak has caused significant global changes and increased public awareness of SARS-CoV-2. Substantial progress in developing vaccines, enhancing sanitation practices, and implementing various measures to combat the virus, including the utilization of probiotics has been made. This comprehensive review examined the medical impact of clinically proven probiotics on infectious diseases, considering three crucial time periods: before (pre-), during (mid-), and after (post-) COVID-19 pandemic era. This review also showed a perspective on the use of probiotics to stimulate the innate immune system and prevent infectious diseases. In pre-COVID-19 era, several probiotic strains were found to be clinically effective in addressing gastrointestinal infectious diseases, the common cold and flu. However, the mechanism by which probiotics exerted their antiviral effects remained relatively unclear during that period. Nevertheless, probiotics,

Indexed as

Communicable DiseasesCOVID-19ProbioticsVaccinesAntiviral AgentsHumansInterferonsPandemicsRNA, ViralSARS-CoV-2Antiviral AgentsInterferonsRNA, ViralVaccinesCOVID-19infectious diseaseinnate immunityLC-plasmaprobiotics

Identifiers

PMID38116008
PMCPMC10728489
OpenAlexW4389345280

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.